Aiming to bring relief and improved quality of life for people with GERD
The objective of our science is clear – developing an effective treatment for people living with gastroesophageal reflux disease (GERD) with sufficient disease control. Time has now come for the next leap forward in treating acid-related diseases. With the development of our drug candidate, linaprazan glurate, our ambition is to improve the quality of life for these people.
Billions of people around the world suffer from Gastroesophageal reflux disease, GERD. Still, present treatment methods and PPI-based drugs are not effective enough for all types of GERD. Heartburn is a common discomfort, caused by light versions of GERD. In severe stages, other symptoms and pain related to acid attacks often occur. Stomach tissue might also be affected or injured.
Our drug candidate represents a new and novel mode of action with superior efficacy potential and pharmacokinetic profile. Linaprazan glurate is a Potassium-Competitive Acid Blocker (P-CAB) and a prodrug of linaprazan, a substance initially developed and tested by AstraZeneca. The gastric acid control ability of linaprazan glurate has in studies shown to be superior to current medication.
The path to value creation
Our goals are set, and we are preparing for the next step in taking linaprazan glurate to the market. After evaluating the results of the ongoing clinical testing phase, we will proceed in fine-tuning and adjusting linaprazan glurate to be an effective treatment for unmet medical needs in eGERD and GERD.
The ongoing clinical development and testing of linaprazan glurate is showing promising results in acid control and in lowering the Cmax-value. Follow the progress and further development.